Bioventus Inc Class A BVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BVS is a good fit for your portfolio.
News
-
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
-
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
-
INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder Investigation of Bioventus Inc. (NASDAQ: BVS) and Encourages Long-Term Investors to Contact the Firm
-
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Trading Information
- Previous Close Price
- $4.16
- Day Range
- $4.07–4.12
- 52-Week Range
- $0.89–6.06
- Bid/Ask
- $4.07 / $4.11
- Market Cap
- $324.58 Mil
- Volume/Avg
- 10,567 / 145,371
Key Statistics
- Price/Earnings (Normalized)
- 115.76
- Price/Sales
- 0.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 970
- Website
- https://www.bioventus.com
Comparables
Valuation
|
Metric
|
BVS
|
ZIMV
|
MMSI
|
|---|---|---|---|
Price/Earnings (Normalized) | 115.76 | 9.69 | 24.64 |
Price/Book Value | 1.89 | 1.05 | 3.57 |
Price/Sales | 0.51 | 0.91 | 3.44 |
Price/Cash Flow | 12.56 | 12.29 | 20.12 |
Price/Earnings
BVS
ZIMV
MMSI
Financial Strength
|
Metric
|
BVS
|
ZIMV
|
MMSI
|
|---|---|---|---|
Quick Ratio | 0.91 | 0.84 | 3.81 |
Current Ratio | 1.53 | 2.78 | 5.45 |
Interest Coverage | −1.98 | −1.51 | 8.07 |
Quick Ratio
BVS
ZIMV
MMSI
Profitability
|
Metric
|
BVS
|
ZIMV
|
MMSI
|
|---|---|---|---|
Return on Assets (Normalized) | 1.03% | 14.12% | 9.43% |
Return on Equity (Normalized) | 4.65% | 31.63% | 14.77% |
Return on Invested Capital (Normalized) | 6.21% | 18.79% | 11.47% |
Return on Assets
BVS
ZIMV
MMSI
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Zgrrybs | Kkcnr | $185.5 Bil | |
SYK
| Stryker Corp | Tfrljyjdm | Rkj | $128.2 Bil | |
MDT
| Medtronic PLC | Lrkzbwqzx | Qrcsr | $106.7 Bil | |
BSX
| Boston Scientific Corp | Yqcnhnd | Xbvbmq | $99.0 Bil | |
DXCM
| DexCom Inc | Hmfvrqpgzw | Tpd | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Jdcflsmqc | Lrktytn | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Txspclsk | Gdxm | $24.9 Bil | |
ALGN
| Align Technology Inc | Bpvzqyflz | Wpfxrr | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Sblpdcr | Swzvt | $18.9 Bil | |
PODD
| Insulet Corp | Xdyhkgyt | Zhhyljv | $11.7 Bil |